H. Lee Moffitt Cancer Center and Research Institute, Inc.

Board Nf Regents the Inivercitvof Texas Cvctom

University of Texas System

Jeffrey S Weber

James J Mulé

Wenshi Wang

Bin Yu

Amod A Sarnaik

Shari Pilon-Thomas

Laszlo G Radvanyi

Jessica Ann Chacon

MacLean S Hall

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

Growing community of inventors

Tampa, FL, United States of America

Jeffrey S Weber